Preclinical studies have shown that blockade of VEGFR2 sensitizes breast tumors to PD-1 blockade, as it promotes the secretion of osteopontin by CD8 T cells, which subsequently induces the production of TGF-β by tumor cells, thereby upregulating PD-1 expression in immune cells [179]. This evidence concerns the gene CD8A and neoplasm.